| Name | Title | Contact Details |
|---|
RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force of approximately 40 sales representatives promoting two speciality gastrointestinal products in select U.S. territories. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise. '
Acatris Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
Covidien Ltd. (Covidien) is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Covidien is part of the local fabric of the communities in which we operate around the world. Our success is made possible through the dedication of our 43,000 employees, nearly two-thirds of whom work in 51 manufacturing facilities located in 18 countries. Every day, over 5,500 Covidien sales representatives meet the needs of our customers in 70 countries. In all, our Company derives 45% of its sales from outside the United States. Covidien, formerly Tyco Healthcare, is a medical equipment and supply company, incorporated in Dublin, Ireland, although its corporate offices are located in Mansfield, Massachusetts, USA. On June 29, 2007, Covidien became an independent publicly traded company after being spun off from Tyco International.
Cabrellis is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.